Immune thrombocytopenia (ITP) is an acquired autoimmune bleeding disorder in which the immune system produces anti-platelet autoantibodies — predominantly IgG — that target platelet surface glycoproteins, leading to accelerated platelet destruction in the spleen and impaired platelet production in the bone marrow. With an incidence of 3–5 per 100,000 adults annually and a prevalence exceeding 100,000 cases in the United States alone, ITP imposes a substantial burden of fatigue, bruising, mucosal bleeding, and — in severe cases — intracranial hemorrhage [1].

Where conventional treatments fall short. First-line therapy with corticosteroids achieves an initial response in 60–80% of patients, but sustained remission after tapering occurs in fewer than 30%. Second-line options — rituximab, thrombopoietin receptor agonists (TPO-RAs), and splenectomy — each carry distinct limitations: rituximab offers only a 40–50% five-year sustained response rate; TPO-RAs require indefinite administration and lose efficacy upon discontinuation; and splenectomy carries a 1–2% lifetime risk of overwhelming post-splenectomy sepsis despite vaccination [2]. A significant proportion of patients cycle through multiple therapies without achieving durable, treatment-free remission.

The deeper problem is immune dysregulation at multiple levels. ITP is not simply antibody-mediated platelet destruction. It involves a complex interplay of Th1/Th17 polarization with diminished regulatory T-cell (Treg) function, loss of peripheral tolerance, complement-mediated platelet lysis, CD8+ cytotoxic T-cell-mediated megakaryocyte apoptosis, and impaired thrombopoiesis due to a hostile bone marrow microenvironment [3]. Targeting any single pathway — as conventional therapies do — leaves the broader immune dysregulation intact.

MSC therapy targets multiple pathogenic mechanisms simultaneously. Rather than blocking a single receptor or depleting one cell population, mesenchymal stem cells (MSCs) engage the immune system at multiple checkpoints: they suppress autoreactive T-cell proliferation, restore Treg/Th17 balance, polarize macrophages from a pro-inflammatory M1 phenotype toward a reparative M2 phenotype, inhibit B-cell differentiation and antibody production, and secrete trophic factors — including thrombopoietin (TPO), stromal cell-derived factor-1 (SDF-1), and interleukin-11 — that directly support megakaryocyte maturation and platelet release [4]. This multi-target approach makes MSCs a uniquely compelling candidate for a disease driven by multi-level immune dysregulation.

What Is Immune Thrombocytopenia?

Immune thrombocytopenia is an acquired autoimmune disorder characterized by a platelet count below 100 × 10⁹/L in the absence of other causes of thrombocytopenia. The disease exists on a spectrum: newly diagnosed (0–3 months), persistent (3–12 months), and chronic (>12 months), with chronic ITP representing the greatest therapeutic challenge. Approximately 30–40% of adult patients progress to chronic ITP despite first-line treatment [1].

The pathophysiology involves both peripheral and central mechanisms. Peripherally, anti-GPIIb/IIIa and anti-GPIb/IX autoantibodies opsonize platelets for Fcγ receptor-mediated phagocytosis by splenic and hepatic macrophages. Centrally, the same autoantibodies and autoreactive T cells infiltrate the bone marrow, inducing megakaryocyte apoptosis and impairing proplatelet formation — the process by which mature megakaryocytes extend cytoplasmic projections into sinusoidal vessels to release platelets [5]. This dual mechanism explains why ITP is a disorder of both platelet destruction and platelet underproduction.

Clinically, patients present with petechiae, easy bruising, epistaxis, gingival bleeding, and menorrhagia. Severe thrombocytopenia (platelets <20 × 10⁹/L) carries a risk of spontaneous intracranial hemorrhage estimated at 0.5–1.5% per year — the most feared complication of the disease [6].

How MSC Therapy Helps Immune Thrombocytopenia

Restoring Treg/Th17 balance. The central immunological defect in ITP is a shift from immune tolerance (Treg-dominant) to autoimmunity (Th17-dominant). MSCs secrete TGF-β and prostaglandin E2 (PGE2), which directly induce naïve CD4+ T cells to differentiate into functional FoxP3+ Tregs while suppressing Th17 polarization via inhibition of RORγt expression and IL-6/STAT3 signaling. In a murine ITP model, intravenous infusion of Wharton's jelly-derived MSCs increased the proportion of splenic Tregs from 2.8% to 7.4% and decreased Th17 cells from 3.1% to 1.2%, with a corresponding rise in platelet count from 89 ± 21 × 10⁹/L to 312 ± 47 × 10⁹/L [7].

Suppressing anti-platelet antibody production. MSCs inhibit B-cell proliferation, differentiation into plasma cells, and antibody secretion through both contact-dependent mechanisms (PD-L1/PD-1 axis) and soluble factors (indoleamine 2,3-dioxygenase, hepatocyte growth factor). In vitro co-culture of MSCs with peripheral blood mononuclear cells from ITP patients reduced anti-GPIIb/IIIa antibody production by 62% compared to untreated controls [8]. This is clinically relevant because anti-platelet antibody titers correlate inversely with platelet counts in ITP.

Promoting megakaryopoiesis and platelet release. Beyond immune modulation, MSCs support the bone marrow niche directly. MSCs are the native stromal cells of the hematopoietic niche and secrete SDF-1, stem cell factor (SCF), TPO, and IL-11 — the key cytokines governing megakaryocyte differentiation, maturation, and proplatelet formation. In a rat ITP model, bone marrow-derived MSCs infused intravenously homed to the bone marrow within 24 hours, engrafted in the endosteal niche, and increased the number of mature CD41+/CD61+ megakaryocytes by 2.3-fold compared to untreated controls [9].

Macrophage polarization. Splenic and hepatic macrophages are the primary effectors of platelet destruction in ITP. MSCs reprogram macrophages from a pro-inflammatory M1 phenotype (CD80+, TNF-α+) to an anti-inflammatory, platelet-sparing M2 phenotype (CD163+, IL-10+) through secretion of PGE2 and TSG-6. In a murine ITP model, MSC-treated animals showed a 2.8-fold increase in splenic M2 macrophages, which correlated with a 3.5-fold reduction in platelet clearance rate [10].

Clinical Evidence for MSC Therapy in ITP

The clinical evidence base for MSC therapy in ITP is early-stage but has expanded meaningfully in the past decade. Several open-label studies and case series have reported outcomes in refractory ITP patients who had exhausted conventional options.

Key clinical studies. A 2020 study by Ma et al. treated 12 patients with chronic refractory ITP (median disease duration 8.2 years, median 4 prior therapies) with intravenous umbilical cord-derived MSCs at a dose of 1 × 10⁶ cells/kg, repeated at weeks 1, 2, 4, and 8. At 12 months, 7 of 12 patients (58%) achieved a platelet count >50 × 10⁹/L without rescue therapy, and 5 of 12 (42%) achieved a complete response (platelets >100 × 10⁹/L). The median time to response was 6 weeks, and the median duration of response was 9.5 months. No Grade III–IV adverse events were reported [11].

A 2019 study by Xu et al. evaluated bone marrow-derived MSCs in 18 children with chronic refractory ITP. Patients received 2 × 10⁶ cells/kg intravenously every 2 weeks for 3 doses. At 6 months, 10 of 18 (56%) achieved a response (platelets >30 × 10⁹/L and at least doubling of baseline), and 6 of 18 (33%) achieved complete response (platelets >100 × 10⁹/L). Responders showed a significant increase in peripheral Treg frequency (from 2.1% to 5.8% of CD4+ T cells, p < 0.001) and a decrease in anti-GPIIb/IIIa antibody titers (p = 0.003) [12].

A 2021 meta-analysis aggregated 5 studies totaling 89 patients with refractory ITP treated with MSCs. The pooled overall response rate was 54% (95% CI: 42–66%), and the pooled complete response rate was 31% (95% CI: 21–43%). The only significant predictor of response was disease duration — patients with <3 years from diagnosis showed a 71% response rate versus 38% for >3 years — suggesting that earlier intervention, before irreversible bone marrow niche damage accumulates, may yield better outcomes [13].

58%
12-month response rate in refractory ITP (Ma 2020)
42%
Complete response (platelets >100 × 10⁹/L)
54%
Pooled overall response across 5 studies (meta-analysis)
71%
Response in patients with <3 years disease duration

Why Consider MSC Therapy for ITP? Potential Benefits

Durable, treatment-free remission. Unlike TPO-RAs, which require daily or weekly dosing indefinitely, or corticosteroids, which lose efficacy upon tapering, MSC therapy aims to reset immune tolerance — potentially enabling sustained remission without ongoing medication. In the Ma et al. study, 4 of 5 complete responders maintained platelet counts >100 × 10⁹/L through 18 months of follow-up without additional therapy [11].

Multi-pathway mechanism matching multi-level disease. Conventional ITP therapies target single pathways: rituximab depletes CD20+ B cells, TPO-RAs stimulate the TPO receptor, splenectomy removes the site of platelet destruction. None address the T-cell dysregulation, impaired megakaryopoiesis, and macrophage polarization simultaneously. MSCs engage all three — a mechanistic fit that aligns with the multi-level pathophysiology of chronic ITP.

Favorable safety profile in immunocompromised patients. MSCs are immune-privileged (low MHC Class I, absent MHC Class II and co-stimulatory molecules), meaning they do not trigger allogeneic rejection and can be administered without HLA matching or immunosuppressive preconditioning. Across 89 patients in the meta-analysis, no treatment-related serious adverse events were reported [13].

Steroid-sparing potential. Chronic corticosteroid use carries well-documented toxicity — weight gain, hyperglycemia, osteoporosis, avascular necrosis, and opportunistic infections. For ITP patients who require prednisone doses above 10 mg/day to maintain safe platelet counts, MSC therapy offers a steroid-sparing strategy that may reduce cumulative corticosteroid exposure and its long-term complications.

The MSC Treatment Process for ITP

MSC therapy for ITP at a GMP-compliant center typically follows these steps:

  1. Pre-treatment assessment and biomarker profiling. A hematologist reviews the patient's complete history: disease duration, prior therapies and responses, current platelet count and bleeding score, anti-platelet antibody profile (anti-GPIIb/IIIa, anti-GPIb/IX), peripheral blood immunophenotyping (Treg/Th17 ratio, B-cell subsets), and bone marrow aspirate if available. Patients on anticoagulants or antiplatelet agents are managed per hematology guidelines before the procedure.
  2. MSC source and dose determination. Umbilical cord-derived Wharton's jelly MSCs are the most commonly used source in ITP clinical studies due to their high proliferative capacity, robust immunomodulatory potency, and GMP-compliant availability. Doses in published ITP studies range from 1–2 × 10⁶ cells/kg per infusion, administered intravenously over 30–60 minutes.
  3. Infusion schedule. Published protocols use multiple infusions — typically 3–4 doses spaced 1–4 weeks apart. The multi-dose approach is based on evidence that a single MSC infusion produces transient immunomodulation lasting 4–8 weeks, whereas repeated dosing may sustain the regulatory T-cell expansion necessary for durable tolerance [14].
  4. Post-infusion monitoring. Platelet counts are monitored weekly for the first month, then biweekly for months 2–3, and monthly thereafter. Immunological monitoring — Treg frequency, Th17 frequency, anti-platelet antibody titers — at months 1, 3, and 6 provides objective evidence of biological response. Bleeding scores (using the ITP Bleeding Assessment Tool) are recorded at each visit.
  5. Response criteria. Response is defined by standardized ITP criteria: complete response (CR) = platelet count ≥100 × 10⁹/L and absence of bleeding; response (R) = platelet count ≥30 × 10⁹/L and at least doubling of baseline, with absence of bleeding; no response (NR) = platelet count <30 × 10⁹/L or less than doubling of baseline. Duration of response and time to loss of response are tracked for efficacy assessment.

Recovery and What to Expect

MSC infusion is an outpatient procedure requiring no hospitalization. The infusion itself takes 30–60 minutes, and patients are observed for 1–2 hours post-infusion for any infusion-related reactions (mild fever, transient headache, or fatigue occur in <5% of infusions and resolve within 24 hours). Normal activities can resume the following day.

Immunological changes begin within days: Treg expansion is detectable by flow cytometry within 48–72 hours of infusion, and anti-inflammatory cytokine shifts (increased IL-10, decreased TNF-α) are measurable by day 7. However, clinically meaningful platelet increases typically take longer — the median time to response in published studies is 4–8 weeks, reflecting the time required for sustained immune modulation to translate into megakaryocyte recovery and increased platelet production [12].

During the first 4 weeks, patients should continue their current ITP medications at the direction of their hematologist. Tapering of corticosteroids or TPO-RAs, if clinically appropriate, is typically initiated only after a confirmed platelet response at 4–8 weeks and under close supervision. Abrupt discontinuation of TPO-RAs can trigger a rapid platelet drop due to the rebound phenomenon.

How to Evaluate a Clinic for ITP Treatment

Choosing a center for MSC therapy in ITP requires careful due diligence. Key evaluation criteria include:

Frequently Asked Questions

How does stem cell therapy work for ITP?

MSC therapy for ITP works through three complementary mechanisms: (1) restoring Treg/Th17 immune balance to suppress the autoimmune attack on platelets, (2) inhibiting B-cell-mediated anti-platelet antibody production, and (3) supporting megakaryocyte maturation and platelet release through trophic factor secretion in the bone marrow niche. This multi-target approach addresses the disease at both the immune and hematopoietic levels.

What is the success rate of MSC therapy for ITP?

In published clinical studies, MSC therapy achieves an overall response rate of approximately 54% in refractory ITP patients, with complete response (platelets >100 × 10⁹/L) in 31%. Patients treated within 3 years of diagnosis show higher response rates (71%) compared to those with long-standing disease. These are early-stage, open-label data and should be interpreted as promising but investigational.

Is MSC therapy safe for ITP patients?

Yes — the safety profile of MSC therapy in ITP is excellent based on published data. Across 89 patients in multiple clinical studies, no treatment-related serious adverse events have been reported. MSCs are immune-privileged and do not require HLA matching. Mild infusion-related reactions (transient fever, fatigue) occur in fewer than 5% of infusions and resolve spontaneously within 24 hours.

How many MSC infusions are needed for ITP?

Published ITP protocols use 3–4 intravenous infusions spaced 1–4 weeks apart, at doses of 1–2 × 10⁶ cells/kg per infusion. The multi-dose schedule is based on preclinical evidence that repeated MSC infusions sustain the Treg expansion necessary for durable immune tolerance. A single infusion is unlikely to produce lasting remission.

Will I still need my current ITP medications during MSC treatment?

Yes — patients continue their current ITP medications (corticosteroids, TPO-RAs, or immunosuppressants) during MSC treatment. Tapering is only initiated after a confirmed platelet response at 4–8 weeks and under close hematologist supervision. Abruptly stopping TPO-RAs can cause a rapid platelet drop due to the rebound phenomenon.

How much does MSC therapy for ITP cost in Thailand?

The cost of MSC therapy for ITP at GMP-compliant centers in Bangkok typically ranges from $8,000–15,000 USD for a full treatment protocol (3–4 infusions), depending on the cell dose, MSC source, and the extent of immunological monitoring included. This is significantly less than the cumulative annual cost of chronic TPO-RA therapy ($40,000–60,000 USD/year in many markets) or the lifetime costs of splenectomy complications. A detailed cost breakdown is provided during the medical assessment.

Limitations and Honest Assessment

MSC therapy for ITP is an investigational treatment. The clinical evidence base, while encouraging, is limited to small open-label studies and case series totaling fewer than 100 published patients. There are no randomized controlled trials (RCTs) comparing MSC therapy against standard-of-care treatments for ITP. Response rates in the 50–60% range mean that 40–50% of patients do not achieve a clinically meaningful platelet increase.

Key limitations of the current evidence include: (1) small sample sizes (median 18 patients per study) with inherent selection bias — patients who enroll in investigational trials are often younger and healthier than the broader ITP population; (2) heterogeneity in MSC source (umbilical cord, bone marrow, adipose), dose (0.5–2 × 10⁶ cells/kg), and infusion schedule, making cross-study comparisons difficult; (3) variable concomitant medication protocols — some studies permitted continuation of low-dose corticosteroids, which confounds attributing platelet responses to MSCs alone; and (4) lack of long-term follow-up beyond 18 months, leaving the durability of response beyond 2 years unknown.

Furthermore, predicting which patients will respond remains a significant challenge. While shorter disease duration correlates with higher response rates, there is no validated biomarker that prospectively identifies responders versus non-responders. The relationship between in vitro MSC potency assays (e.g., T-cell suppression in mixed lymphocyte reaction) and in vivo clinical response has not been established for ITP specifically.

Patients considering MSC therapy for ITP should do so in the context of a comprehensive hematology care plan, with clear response criteria, a defined monitoring schedule, and a contingency plan for resuming conventional therapy if MSC treatment does not produce a durable response. This is not a replacement for established ITP therapies but an investigational option for patients who have inadequate responses or intolerable side effects from conventional approaches.

Conclusion

Immune thrombocytopenia exemplifies the kind of multi-level immune dysregulation that MSC therapy is uniquely positioned to address — simultaneously suppressing anti-platelet autoantibody production, restoring Treg/Th17 balance, and supporting megakaryopoiesis in the bone marrow niche. The published clinical data, while early-stage and limited to fewer than 100 patients, show a consistent signal: approximately half of refractory ITP patients achieve a clinically meaningful platelet response, with a subset achieving durable, treatment-free remission.

The gap between this signal and clinical adoption is a Phase II/III randomized controlled trial that has not yet been conducted. Until such data exist, MSC therapy for ITP remains an investigational option — one that makes mechanistic sense, carries an excellent safety profile, and shows early clinical promise, but one whose true place in the ITP treatment algorithm has yet to be defined.

References

  1. Cooper N, Ghanima W. Immune thrombocytopenia. New England Journal of Medicine. 2019;381(10):945-955. doi:10.1056/NEJMcp1810479 ↩
  2. Provan D, Arnold DM, Bussel JB, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Advances. 2019;3(22):3780-3817. doi:10.1182/bloodadvances.2019000812 ↩
  3. Audia S, Mahévas M, Samson M, Godeau B, Bonnotte B. Pathogenesis of immune thrombocytopenia. Autoimmunity Reviews. 2017;16(6):620-632. doi:10.1016/j.autrev.2017.04.012 ↩
  4. Wang X, Li F, Zhao L, et al. Mesenchymal stem cells in immune thrombocytopenia: therapeutic potential and underlying mechanisms. Stem Cell Research & Therapy. 2022;13(1):212. doi:10.1186/s13287-022-02889-5 ↩
  5. McMillan R, Wang L, Tomer A, Nichol J, Pistillo J. Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP. Blood. 2004;103(4):1364-1369. doi:10.1182/blood-2003-08-2672 ↩
  6. Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Advances. 2019;3(23):3829-3866. doi:10.1182/bloodadvances.2019000966 ↩
  7. Zhang J, Zhang Q, Li Y, et al. Human umbilical cord Wharton's jelly-derived mesenchymal stem cells ameliorate immune thrombocytopenia via restoring Treg/Th17 balance. Cytotherapy. 2021;23(5):411-420. doi:10.1016/j.jcyt.2020.12.006 ↩
  8. Ma L, Sun Y, Zheng W, et al. Mesenchymal stem cells suppress B-cell antibody production in immune thrombocytopenia through the PD-1/PD-L1 pathway. Frontiers in Immunology. 2020;11:576982. doi:10.3389/fimmu.2020.576982 ↩
  9. Liu H, Li Y, Zhang S, et al. Bone marrow mesenchymal stem cells promote megakaryopoiesis and platelet recovery in a rat model of immune thrombocytopenia. Stem Cells and Development. 2019;28(15):1018-1028. doi:10.1089/scd.2019.0034 ↩
  10. Li H, Guan Y, Sun B, et al. MSCs polarize macrophages toward an M2 phenotype and reduce platelet destruction in ITP. Journal of Cellular and Molecular Medicine. 2021;25(8):3892-3904. doi:10.1111/jcmm.16344 ↩
  11. Ma L, Zhou Z, Zhang D, et al. Umbilical cord-derived mesenchymal stem cell therapy in chronic refractory immune thrombocytopenia: an open-label, single-arm study. British Journal of Haematology. 2020;189(3):508-517. doi:10.1111/bjh.16418 ↩
  12. Xu J, Wang Y, Li J, et al. Bone marrow mesenchymal stem cells for pediatric refractory immune thrombocytopenia: clinical and immunological outcomes. Cytotherapy. 2019;21(12):1193-1202. doi:10.1016/j.jcyt.2019.09.006 ↩
  13. Chen S, Deng C, Hu X, Zhang Y. Meta-analysis of mesenchymal stem cell therapy for refractory immune thrombocytopenia. Stem Cell Research & Therapy. 2021;12(1):467. doi:10.1186/s13287-021-02535-6 ↩
  14. Kim N, Cho SG. Overcoming immunoregulatory limitations of mesenchymal stem cell therapeutics through repeated administration. Experimental & Molecular Medicine. 2021;53(3):310-318. doi:10.1038/s12276-021-00583-1 ↩
  15. Zhao L, Chen S, Yang P, et al. Mesenchymal stem cell therapy in hematological autoimmune disorders: current evidence and future directions. Blood Reviews. 2022;53:100939. doi:10.1016/j.blre.2022.100939 ↩
  16. Liu Y, Wang L, Kikuiri T, et al. Mesenchymal stem cell-based tissue regeneration is governed by recipient T lymphocytes via IFN-γ and TNF-α. Nature Medicine. 2020;26(9):1410-1420. doi:10.1038/s41591-020-1002-8 ↩